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801Effect of Daily Glucose Fluctuation on Coronary
Plaque Vulnerability in Patients Pre-Treated With
Lipid-Lowering Therapy
A Prospective Observational StudyABSTRACTOBJECTIVES This study sought to investigate the effect of daily glucose ﬂuctuation on coronary plaque properties in
patients with coronary artery disease (CAD) pre-treated with lipid-lowering therapy.
BACKGROUND There is growing evidence that glucose ﬂuctuation, as a residual risk apart from dyslipidemia, is an
important factor contributing to the development of CAD.
METHODS This prospective study enrolled 70 consecutive CAD patients who were referred for percutaneous coronary
intervention and whose low-density lipoprotein cholesterol level was <120 mg/dl under statin treatment or <100 mg/dl
without statins. Daily glucose ﬂuctuation was analyzed by measuring the mean amplitude of glycemic excursion (MAGE).
The plaque properties in the culprit and nonculprit lesions were assessed by virtual histology intravascular ultrasound,
and the volume percentage of necrotic core within the plaque (%NC) and the presence of thin-cap ﬁbroatheroma were
evaluated.
RESULTS In total, 165 lesions were evaluated in 70 patients (40 diabetic and 30 nondiabetic patients). %NC was well
correlated with MAGE (r ¼ 0.490, p <0.001). A linear mixed effect model showed that MAGE had the strongest effect on
%NC (coefﬁcient b ¼ 0.080  0.020 [standard error], p < 0.001). The generalized linear mixed effect model revealed
that MAGE was the only independent predictor of the presence of thin-cap ﬁbroatheroma (odds ratio: 1.037; 95%
conﬁdence interval: 1.010 to 1.065; p ¼ 0.007).
CONCLUSIONS Daily glucose ﬂuctuation may have an effect on coronary plaque vulnerability in patients with CAD
pre-treated with lipid-lowering therapy. Further investigations should address the rationale for the early detection and
control of glucose ﬂuctuation in the era of universal statin use for CAD patients. (J Am Coll Cardiol Intv 2015;8:800–11)
© 2015 by the American College of Cardiology Foundation.S olid evidence has accumulated to show thatintervention against dyslipidemia can preventcoronary artery disease (CAD), and statin
administration is now widely used for both primary
and secondary prevention of CAD. However, the
reduction of risk of CAD by statins has been reported
to be only 30% (1), and the target level of plasma low-
density lipoprotein (LDL) cholesterol is still contro-
versial (2). Thus, there has been a focus on further
managing the residual risk apart from dyslipidemia.
Meanwhile, the number of patients with diabetes
mellitus (DM) has been greatly increasing worldwide,
and the clinical effect of abnormal glucose meta-
bolism has been recognized in the management of
CAD.
There is increasing evidence that the post-prandial
blood glucose state is an important contributing fac-
tor to the development of atherosclerosis (3,4). TheSTOP-NIDDM (Study to Prevent Non-Insulin-Depen-
dent Diabetes Mellitus) trial revealed that a poor post-
prandial state accelerates atherosclerosis, whereas
improving it prevents atherosclerosis progression. It
has long been recognized that glucose levels
measured by a 2-h post-oral glucose tolerance test
(OGTT) are strongly associated with mortality and
cardiovascular disease (5,6). The DECODE (Diabetes
Epidemiology: Collaborative Analysis of Diagnostic
Criteria in Europe) study reported that high blood
glucose concentrations 2 h after OGTT were associ-
ated with an increased risk of death that was inde-
pendent of fasting blood glucose (5). However,
whether glucose ﬂuctuation may affect the coronary
plaque properties in CAD patients pre-treated with
lipid-lowering therapy remains largely unknown.
Virtual histology (VH) intravascular ultrasound
(IVUS), which uses amplitude and frequency analysis
FIGUR
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802of the IVUS backscatter signals, can reliably
identify atherosclerotic plaque components
(7). Reconstructed color-coded tissue maps
with 4 different types of atherosclerotic pla-
que have high in-vitro predictive accuracy
(8,9). This imaging modality enables us to
characterize the coronary plaque component.
The PROSPECT (Providing Regional Obser-
vations to Study Predictors of Events in the
Coronary Tree) study conﬁrmed the clinical
effect of shallow necrotic cores. In a follow-
up of about 700 patients with acute coro-
nary syndrome (ACS) by VH-IVUS examina-
tion, the presence of necrotic core adjacent to
lumen, which is called thin-cap ﬁbroather-
oma (TCFA), emerged as 1 of the most sig-
niﬁcant independent predictors of future
coronary events in nontreated lesions (10).SEE PAGE 812As continuous glucose monitoring (CGM) has
recently become available to evaluate daily glucose
ﬂuctuation in clinical practice, we investigated the
relationship between glucose ﬂuctuation and coro-
nary plaque properties as analyzed by CGM and
VH-IVUS.E 1 Study Population
continuous glucose monitoring; DM ¼ diabetes mellitus; IGT ¼ im
ular ejection fraction; NGT ¼ normal glucose tolerance; PCI ¼ pe
scular ultrasound.METHODS
PATIENT POPULATION. Seventy consecutive pa-
tients who had undergone percutaneous coronary
intervention (PCI) for CAD from June 2012 to May
2014 and who fulﬁlled the inclusion criteria were
enrolled in this prospective registry (Figure 1). Pa-
tients between 20 and 80 years of age whose LDL
cholesterol levels were <120 mg/dl under statin
administration or <100 mg/dl under other treatment
for dyslipidemia, including lifestyle management,
were deemed eligible for inclusion. Stable angina is
deﬁned as a clinical syndrome characterized by
discomfort in the chest, shoulder, or back, typically
elicited by exertion or emotional stress and relieved
by rest or nitroglycerin (11). The study exclusion
criteria were: 1) PCI for acute coronary syndrome;
2) unsuitable anatomy for VH-IVUS; 3) presented with
cardiogenic shock or low left ventricular ejection
fraction (<35%); 4) concomitant inﬂammatory con-
ditions (such as active infection, inﬂammatory
arthritis, or connective tissue disease) or malig-
nancies; and 5) dependence on hemodialysis. Among
70 patients enrolled, 23 were formerly diagnosed as
having type 2 DM. The remaining 47 patients, who
had not been diagnosed with glucose intolerance,
were classiﬁed into the following 3 groups, on thepaired glucose tolerance; LDL ¼ low-density lipoprotein; LVEF ¼ left
rcutaneous coronary intervention; VH-IVUS ¼ virtual histology
FIGURE 2 Study Protocol
On admission, a blood sample analysis and 75-g oral glucose tolerance test (OGTT) were
performed under fasting conditions. Subcutaneous interstitial glucose levels were moni-
tored over a period of 3 consecutive days using CGM. After the CGM examination, 3 vessels
were subjected to a VH-IVUS. Abbreviations as in Figure 1.
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803basis of the results of a 75-g OGTT: 1) normal glucose
tolerance (NGT), deﬁned as fasting plasma glucose
(FPG) level <110 mg/dl and 2-h plasma glucose (PG)
level <140 mg/dl (n ¼ 10); 2) impaired glucose toler-
ance (IGT), deﬁned as FPG level <126 mg/dl and 2-h
PG level of 140 to 200 mg/dl (n ¼ 20); and 3) newly
diagnosed type 2 DM, deﬁned as FPG level >126
mg/dl or 2-h PG >200 mg/dl (n ¼ 17). We divided the
patients into 2 groups according to whether or not
they met the DM criteria (DM group and non-DM
group). Duration of DM was deﬁned as the time
period between the time of diagnosis and the time of
examination.
This study was approved by the ethics committee
of Kobe University and was carried out according to
the guidelines of the Declaration of Helsinki. All
enrolled study patients provided their written
informed consent for enrollment into the study.
STUDY PROTOCOL. On admission, a blood sample
analysis was performed under fasting conditions to
evaluate levels of creatinine, glycosylated hemoglo-
bin (HbA1c), total cholesterol, LDL cholesterol, high-
density lipoprotein cholesterol, triglycerides, and
C-reactive protein (CRP). In addition, a 75-g OGTT was
performed in all patients, and levels of PG and
immunoreactive insulin were evaluated just before
and 30, 60, 90, and 120 min after the oral glucose
load.
Subcutaneous interstitial glucose levels were
monitored over a period of 3 consecutive days usingFIGURE 3 Representative VH-IVUS Images and TCFA
Representative longitudinal virtual histology-intravascular ultrasound (V
the target area (B). The table shows the ratio of each plaque componen
TCFA was deﬁned as a lesion meeting the following criteria: 1) necrotic-
ﬁbrous component; and 2) % plaque volume >40% in at least 3 consecu
core in contact with luminal border.the CGM System iPro2 (Medtronic, Northridge,
California).
After the CGM examination, all patients underwent
a catheterization procedure for PCI to native coronary
arteries, and 3 vessels were subjected to VH-IVUS
examination (Eagle Eye Platinum 3.5F 20-MHz,
Volcano Corp., Rancho Cordova, California). In addi-
tion to the culprit lesions for PCI, nonculprit lesions
were evaluated with VH-IVUS. Nonculprit lesions
were deﬁned as angiographically intermediate lesions
(diameter stenosis 30% to 70%) with an IVUS mini-
mum lumen area <4 mm2 with 50% to 70% plaque
burden. The IVUS procedure was performed in
a standard fashion, using automated motorized
0.5 mm/s pullback (Figure 2). Culprit lesions
were identiﬁed by analyzing pre- and inter-crisisH-IVUS) images (A) and VH-IVUS cross-sectional images along
t. (C) A representative case of thin-cap ﬁbroatheroma (TCFA).
core rich lesion (%NC >10%) without evidence of an overlying
tive frames by VH-IVUS analysis. White arrowheads indicate necrotic
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804electrocardiograms, left ventricular wall motion ab-
normalities, and angiographic lesion appearance.
CGM SYSTEM AND ANALYSIS OF GLUCOSE
FLUCTUATION. CGM was performed for 3 consecu-
tive days before PCI, and the daily glucose proﬁle was
analyzed using data obtained on days 2 and 3 to avoid
any bias due to either insertion or removal of the
sensor. In all patients, the CGM analysis software
(CareLink iPro, Medtronic, Northridge, California)
calculated the median of the variables measured on
days 2 and 3: 24-h mean glucose levels, the time in
hyperglycemia/hypoglycemia, and the mean ampli-
tude of glycemic excursions (MAGE). MAGE, which
was proposed by Service et al. (12), represents ﬂuc-
tuations in blood glucose levels over a 24-h period
and was calculated from the daily variations in blood
glucose level, measured continuously by CGM over a
period of 2 days. Time in hyperglycemia and hypo-
glycemia were deﬁned as the time when blood
glucose levels were >140 and <70 mg/dl, respec-
tively. All patients received optimal meals (25 to
28 kcal/kg of ideal body weight; 60% carbohydrate,
15% to 20% protein, and 20% to 25% fat) during CGM.
IVUS AND VH-IVUS ANALYSIS. Measurements were
made of the target vessel, which was deﬁned as theFIGURE 4 Classiﬁcation of Glucose Tolerance
Subjects included 23 formerly diagnosed with DM (33%) (blue),
17 with newly diagnosed DM (24%) (red), 20 patients with IGT
(29%) (green), and only 10 with NGT (14%) (purple), totaling to
40 DM and 30 non-DM patients. Abbreviations as in Figure 1.segment from distal to the target lesion to the cor-
onary ostium, evaluating a minimal length of
30 mm. Manual contour detection of both the lumen
and the media adventitia interface was performed by
2 experienced analysts (M.K. and H.O.) who were
blinded to baseline clinical and angiographic lesion
characteristics. We analyzed the whole lesion vol-
ume and calculated the lumen, vessel, and plaque
(vessel  lumen) volumes using Simpson’s method.
Interobserver and intraobserver analyses were also
performed by these analysts. Intraclass correlation
coefﬁcient for interobserver and intraobserver re-
liabilities of the external elastic membrane volume
were 0.952 and 0.968, respectively. VH-IVUS auto-
matically classiﬁed the plaque into 4 major compo-
nents (ﬁbrous [labeled green], ﬁbrofatty [labeled
greenish-yellow], necrotic core [NC] [labeled red],
and dense calcium [labeled white]) (8). The ratio of
each plaque component in both culprit and non-
culprit lesions was expressed as a percentage of total
plaque volume (Figures 3A and 3B). According to the
relative amounts of the 4 components, TCFA was
deﬁned as a lesion meeting the following criteria: 1)
necrotic-core–rich lesion (%NC >10%) without evi-
dence of an overlying ﬁbrous component and; 2) %
plaque volume >40% in at least 3 consecutive
frames by VH-IVUS analysis (13) (Figure 3C). The
presence of TCFA required the agreement of 2 in-
dependent experienced observers (M.K. and H.O.),
and when there was discordance between the ob-
servers, a consensus reading was obtained from a
third independent reviewer (T.S.). Interobserver and
intraobserver agreements for the detection of TCFA
were within an acceptable range (interobserver:
kappa ¼ 0.927, intraobserver; kappa ¼ 0.887).
STATISTICAL ANALYSIS. All data are presented as
mean  SD or proportions. Categorical variables were
compared using the Fisher exact test and the Student
t test for continuous variables, as appropriate. Simple
linear correlations were calculated using the concept
of least squares and by determining the Pearson cor-
relation coefﬁcient, r (* and y represent p < 0.05 and
p < 0.001 for the correlation with % NC, respectively).
Linear mixed effect models were used to explore the
inﬂuence of different variables on the percentage of
necrotic core within the plaque and to adjust for
covariates. Generalized linear mixed effect models
were also used to assess the effect of a set of factors
on TCFA. Univariate analysis was ﬁrst performed, and
all variables that satisﬁed p < 0.2 were entered en
bloc in the multivariate model, along with age and sex
as background variables. In both the linear mixed
effect model and generalized linear mixed effect
TABLE 1 Baseline Patient Characteristics
Overall
(n ¼ 70)
DM
(n ¼ 40)
Non-DM
p Value
DM vs. Non-DM
All Non-DM
(n ¼ 30)
IGT
(n ¼ 20)
NGT
(n ¼ 10)
Age, yrs 70.1  10.5 70.3  10.4 70.2  10.7 70.1  11.2 70.3  10.1 0.96
BMI, kg/m2 24.3  3.3 24.8  3.0 23.5  3.6 24.0  3.4 22.5  4.0 0.09
Male 59 (84) 33 (83) 26 (87) 18 (90) 8 (80) 0.45
Hypertension 53 (76) 31 (78) 22 (73) 14 (70) 8 (80) 0.68
Dyslipidemia 61 (87) 36 (90) 25 (83) 16 (80) 9 (90) 0.32
Smoking 48 (69) 28 (70) 20 (67) 15 (75) 5 (5) 0.76
Current 17 (24) 11 (27) 6 (20) 5 (25) 1 (1)
Former (quit >3 months) 31 (44) 17 (43) 14 (47) 10 (50) 4 (4)
Prior myocardial infarction 16 (23) 9 (23) 7 (23) 2 (10) 5 (50) 0.93
Prior PCI 35 (50) 21 (52) 14 (47) 10 (50) 4 (40) 0.63
Prior CABG 1 (1) 0 (0.0) 1 (3) 0 (0) 1 (10) 0.26
Systolic blood pressure, mm Hg 121.6  12.1 121.8  12.9 121.5  11.1 120.6  9.4 123.1  14.1 0.91
Diastolic blood pressure, mm Hg 62.6  7.8 62.0  8.2 63.6  7.2 62.7  7.5 65.2  6.4 0.40
Left ventricular ejection fraction, % 59.6  9.9 60.4  7.7 58.5  12.6 60.0  10.6 55.7  16.1 0.45
Duration of DM, yrs 4.9  9.1 8.5  10.6 — — — —
HbA1c (NGSP) (%) 6.4  0.9 6.8  1.0 5.8  0.3 5.8  0.3 5.7  0.3 <0.001
1,5-AG, mg/ml 15.7  8.0 12.8  6.4 19.5  8.3 19.3  9.4 19.9  6.0 <0.001
Glycoalbumin, % 16.6  3.0 17.7  3.2 15.1  1.7 15.2  1.6 14.8  1.8 <0.001
75-g OGTT
Fasting PG, mg/dl 103.1  20.9 114.5  22.3 90.2  7.7 91.6  7.8 87.6  7.4 <0.001
2-h PG, mg/dl 213.0  83.6 270.8  71.3 147.4  32.4 165.4  17.8 111.3  23.3 <0.001
Fasting IRI, mU/ml 7.1  5.7 7.7  6.9 6.3  3.8 6.2  3.5 6.5  4.6 0.32
2-h IRI, mU/ml 95.3  94.0 102.1  108.5 87.4  74.6 103.9  84.6 56.2  37.1 0.54
HOMA R 1.9  2.3 2.4  3.0 1.4  0.8 1.4  0.7 1.4  1.0 0.09
HOMA b 73.5  56.4 58.1  37.7 91.0  68.5 87.3  65.2 98.4  77.8 0.024
Total cholesterol, mg/dl 155.0  26.8 154.4  27.4 155.3  26.6 149.8  25.1 166.4  27.3 0.94
LDL cholesterol, mg/dl 87.8  18.7 88.1  20.1 87.4  17.0 85.6  17.9 91.1  15.1 0.88
HDL cholesterol, mg/dl 46.0  12.0 44.1  10.9 48.4  13.1 47.5  13.2 50.4  13.3 0.14
Triglyceride, mg/dl 128.5  60.6 140.1  57.7 113.7  62.0 113.0  69.8 115.3  45.9 0.07
CRP, mg/dl 0.17  0.28 0.14  0.22 0.20  0.34 0.26  0.40 0.10  0.11 0.39
Creatinine, mg/dl 0.98  0.32 1.03  0.36 0.93  0.24 0.91  0.20 0.97  0.31 0.20
Medication on admission
Aspirin 58 (83) 34 (85) 24 (80) 18 (90) 6 (60) 0.32
Thienopyridine 32 (46) 20 (50) 12 (40) 8 (40) 4 (40) 0.35
Statin 53 (76) 32 (80) 21 (70) 13 (65) 8 (80) 0.33
EPA 3 (4) 2 (13) 1 (3) 1 (5) 0 (0.0) 0.61
Ezetimibe 6 (9) 5 (13) 1 (3) 1 (5) 0 (0.0) 0.18
Fibrate 2 (3) 1 (3) 1 (3) 1 (5) 0 (0.0) 0.68
ACE-I/ARB 44 (63) 26 (67) 18 (60) 13 (65) 5 (50) 0.57
Beta-blocker 30 (43) 19 (22) 11 (37) 8 (40) 3 (30) 0.32
Insulin 4 (6) 4 (10)
Metformin 6 (9) 6 (15)
SU 13 (19) 13 (33)
a-GI 4 (6) 4 (10)
Glinide 0 (0) 0 (0)
Pioglitazone 0 (0) 0 (0)
DPP4-I 16 (23) 16 (40)
Values are mean  SD or n (%).
1,5 AG ¼ 1,5 anhydroglucitol; a-GI ¼ a-glucosidase inhibitor; ACE-I ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin II receptor blocker; BMI ¼ body mass
index; CABG¼ coronary artery bypass graft; CRP ¼ C-reactive protein; DM¼ diabetes mellitus; DPP4-I¼ dipeptidyl peptidase-4 inhibitor EPA ¼ eicosapentaenoic acid; HbA1c¼
glycated hemoglobin; HDL ¼ high-density lipoprotein; HOMA B¼ homeostasis model assessment beta; HOMA R¼ homeostasis model assessment ratio; IGT ¼ impaired glucose
tolerance; IRI ¼ immunoreactive insulin; LDL ¼ low-density lipoprotein; NGT ¼ normal glucose tolerance; OGTT ¼ oral glucose tolerance test; PCI ¼ percutaneous coronary
intervention; PG ¼ plasma glucose; SU ¼ sulfonylurea.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 6 , 2 0 1 5 Kuroda et al.
M A Y 2 0 1 5 : 8 0 0 – 1 1 Glucose Fluctuation Causes Plaque Vulnerability
805
TABLE 2 Variables Measured by the Continuous Glucose Monitoring System
Overall
(n ¼ 70)
DM
(n ¼ 40)
Non-DM
p Value
DM vs. Non-DM
All Non-DM
(n ¼ 30)
IGT
(n ¼ 20)
NGT
(n ¼ 10)
MAGE, mg/dl 72.7  35.1 82.1  34.1 60.1  32.9 63.6  32.9 52.8  33.6 0.008
Mean BG, mg/dl 134.7  29.0 149.4  30.7 115.5  8.5 117.1  7.8 112.4  9.5 <0.001
Max BG, mg/dl 216.3  49.6 238.4  48.7 187.5  33.8 190.2  31.4 182.2  39.3 <0.001
Min BG, mg/dl 78.0  28.4 85.7  32.4 67.8  18.0 69.9  18.5 63.8  17.1 0.005
Time in hyperglycemia, h 26.2  25.7 39.3  27.2 9.1  6.8 10.6  6.6 5.7  6.1 <0.001
Time in hypoglycemia, h 1.3  2.6 0.8  1.7 2.0  3.4 2.1  3.9 1.7  2.0 0.094
Values are mean  SD. Time in hyperglycemia was deﬁned as the time when blood glucose levels were above 140 mg/dl. Time in hypoglycemia was deﬁned as the time when
blood glucose levels were under 70 mg/dl.
BG ¼ blood glucose; MAGE ¼ mean amplitude of glycemic excursion; other abbreviations as in Table 1.
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806model, patients were treated as random effect vari-
ables. To assess the interobserver and intraobserver
variability, the results were compared with the kappa
test of concordance to the categorical data, and
a Bland-Altman plot was fulﬁlled for continuous
data. Analyses were performed using commercially
available software (SPSS version 22, IBM Corp.,
Armonk, New York). Values of p < 0.05 were consid-
ered statistically signiﬁcant.TABLE 3 Plaque Characteristics Evaluated by VH-IVUS
Plaque Analysis
Overall
(n ¼ 165)
DM
(n ¼ 100)
Al
Culprit lesion 55 (33) 37 (37)
Plaque location
LAD 53 (32) 35 (35)
LCx 55 (33) 33 (33)
RCA 50 (30) 27 (27)
LMT 7 (4) 5 (5)
Plaque volume
Absolute data, mm3 107.6  73.3 107.7  68.5 107
Plaque burden, % 56.5  8.8 56.8  8.8 56
Lesion length, mm 14.2  8.3 14.2  8.3 14
Fibrous
Absolute data, mm3 40.2  32.4 40.2  29.6 40
Relative data, % 59.1  8.9 58.1  9.2 60
Fibrofatty
Absolute data, mm3 9.1  8.3 8.8  7.9 9
Relative data, % 13.4  7.4 12.7  7.4 14
Dense-calcium
Absolute data, mm3 5.4  5.5 5.7  5.6 4
Relative data, % 8.1  6.3 8.7  6.8
Necrotic core
Absolute data, mm3 13.9  12.8 14.6  11.9 12
Relative data, % 19.3  5.9 20.4  5.5 17
Thin-cap ﬁbroatheromas 15 (9) 13 (13)
Values are n (%) or mean  SD.
LAD ¼ left anterior descending artery; LCx ¼ left circumﬂex artery; LMT ¼ left mainRESULTS
BASELINE PATIENT CHARACTERISTICS. Between
June 2012 and May 2014, a total of 70 patients were
enrolled (Figure 4). Baseline patient characteristics
and medications on admission are shown in Table 1.
No signiﬁcant differences between the DM and non-
DM groups were observed in the baseline character-
istics, except for glycemic variables such as HbA1c,Non-DM
p Value
DM vs. Non-DM
l Non-DM
(n ¼ 65)
IGT
(n ¼ 48)
NGT
(n ¼ 17)
18 (28) 12 (25) 6 (35) 0.21
0.90
18 (27) 13 (27) 5 (29)
22 (34) 16 (33) 6 (35)
23 (35) 17 (35) 6 (35)
2 (3) 2 (4) 0 (0)
.3  80.5 116.4  86.2 81.4  55.9 0.97
.1  8.9 56.5  8.9 54.5  9.0 0.63
.3  8.2 14.7  8.5 13.2  7.4 0.87
.2  36.5 44.4  39.6 28.2  22.9 0.99
.7  8.2 60.4  7.8 61.4  9.6 0.070
.6  8.9 10.4  9.8 7.0  5.7 0.57
.4  7.3 13.8  6.6 16.1  8.9 0.15
.8  5.2 5.3  5.5 3.2  3.8 0.27
7.1  5.2 7.2  4.9 6.8  6.3 0.086
.9  14.1 14.5  15.0 8.4  9.9 0.41
.7  6.3 18.5  5.9 15.6  7.1 0.004
2 (3) 2 (4) 0 (0) 0.030
trunk; RCA ¼ right coronary artery; other abbreviations as in Table 1.
TABLE 4 Pearson Correlation Coefﬁcients
Overall DM Non-DM
Fasting PG 0.172* 0.127 0.077
OGTT 2-h PG 0.242† 0.121 0.276*
Fasting IRI 0.027 0.005 0.017
OGTT 2-h IRI 0.080 0.097 0.080
MAGE 0.490† 0.410† 0.511†
Mean BG by CGM 0.337† 0.376† 0.066
Time in hyperglycemia 0.285† 0.266† 0.176
Time in hypoglycemia 0.184* 0.035 0.416†
HbA1c 0.276† 0.230* 0.148
1,5 AG 0.275† 0.275† 0.101
Glycoalbumin 0.302† 0.260* 0.102
Duration of DM 0.233† 0.205* —
HOMA-R 0.046 0.005 0.006
HOMA-b 0.091 0.156 0.053
HDL cholesterol 0.069 0.037 0.113
LDL cholesterol 0.035 0.008 0.106
TG 0.042 0.198 0.059
CRP 0.122 0.024 0.308*
Creatinine 0.002 0.056 0.005
Age 0.125 0.172 0.064
BMI 0.091 0.016 0.153
Systolic blood pressure 0.088 0.018 0.027
Diastolic blood pressure 0.074 0.102 0.082
Values are r values. Association between the percentage of necrotic core within
the plaque and clinical and laboratory variables. *p < 0.05, †p < 0.001.
Abbreviations as in Tables 1 and 2.
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8071,5-AG, and glycoalbumin levels. According to the
75-g OGTT data, FPG and 2-h PG levels were signiﬁ-
cantly higher in the DM group than in the non-DM
group. Medications on admission did not differ
between the 2 groups, except for diabetes drug usage.
The variables measured by CGM are summarized in
Table 2. All variables had signiﬁcantly greater values
in the DM group than in the non-DM group, except
that the time in hypoglycemia tended to be longer in
the non-DM group than in DM group.TABLE 5 Linear Mixed Effect Model Adjusted With Confounders
Coefﬁcients
t p ValueB SE
All patients (n ¼ 165)
MAGE 0.080 0.020 3.930 <0.001
Duration of DM 0.146 0.097 1.505 0.140
DM patients (n ¼ 100)
MAGE 0.054 0.027 1.981 0.060
Duration of DM 0.132 0.098 1.354 0.191
Non-DM patients (n ¼ 65)
MAGE 0.135 0.035 3.905 0.001
The percentage of necrotic core within the plaque is the dependent variable. All
models were adjusted by age, sex, HbA1c, fasting PG, 1,5-AG, glycoalbumin, and
2-h PG.
Abbreviations as in Tables 1 and 2.PLAQUE CHARACTERISTICS OBTAINED BY IVUS.
A total of 165 plaques were identiﬁed in 70 patients:
100 plaques in 40 DM patients (2.5 plaques/patient)
and 65 plaques in 30 non-DM patients (2.2 plaques/
patient); 33% of plaques were in the culprit lesion.
A total of 30 patients underwent a 3-vessel IVUS
examination, whereas the remaining 40 patients un-
derwent a 1- or 2-vessel IVUS examination. The pla-
que characteristics are shown in Table 3. The %NC
was signiﬁcantly higher in the DM group than in the
non-DM group, whereas the percentage of ﬁbrous
component tended to be lower in the DM group.
Compared with plaques in the non-DM group, those
in the DM group had a signiﬁcantly higher incidence
of TCFA (13% vs. 2%, p ¼ 0.030).
RELATIONSHIPS BETWEEN %NC AND CLINICAL AND
LABORATORY VARIABLES. The %NC was tested for
simple linear correlations against markers of glucose
control and other laboratory variables (Table 4). In all
patients, the strongest correlation was found between
%NC and MAGE (r ¼ 0.490; p < 0.001). In contrast,
clinical and laboratory data other than glycemic var-
iables were not correlated with %NC. When analyzed
separately, in both the DM and non-DM groups,
the strongest correlation was found with MAGE
(r ¼ 0.410, p < 0.001; and r ¼ 0.511, p < 0.001,
respectively). In non-DM patients, the time in hypo-
glycemia and CRP level were signiﬁcantly correlated
with %NC.
The linear mixed effect model adjusted with con-
founders was used to assess the independent effects
of diabetic parameters on %NC (Table 5). In the entire
patient population, multivariate analysis demon-
strated that a larger MAGE was signiﬁcantly associ-
ated with a higher %NC, whereas a longer duration of
DM had a tendency toward a higher %NC. In the non-
DM group, a larger MAGE was the only independent
predictor of a higher %NC.
RELATIONSHIPS BETWEEN MAGE AND COMPONENTS
WITHIN THE PLAQUE. MAGE was assessed for simple
linear correlations with other components within
the plaque. The percentage of ﬁbrous component
had a negative correlation, whereas the percentage
of calcium had a positive correlation both in culprit
and nonculprit lesions (Figures 5A to 5C). The cor-
relation coefﬁcient between %NC and MAGE in
culprit lesions was numerically higher than that
in nonculprit lesions (r ¼ 0.533 vs. r ¼ 0.465,
respectively).
In addition, the correlation with MAGE and %NC
was assessed in DM, IGT, and NGT patients (Figure 6).
In DM, IGT, and NGT patients, MAGE had a signiﬁcant
positive correlation with %NC.
FIGURE 5 The Correlation Between MAGE and Plaque Component
The correlation between mean amplitude of glycemic excursion (MAGE) and the percentage of (left) necrotic core, (middle) ﬁbrous component,
and (right) calcium in (A) all plaques, (B) culprit plaques, and (C) nonculprit plaques.
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LABORATORY VARIABLES. Generalized linear mixed
effect model was applied to identify independent risk
factors for TCFA (Table 6). Univariate analysis was
ﬁrst conducted to identify potential factors for TCFA.
All variables with p < 0.2 on univariate analysis were
tested by multivariate analysis. In all plaques, MAGE
was the only independent predictor of TCFA (odds
ratio: 1.037; 95% conﬁdence interval: 1.010 to 1.065;
p ¼ 0.007).
DISCUSSION
The current study represents an in vivo report to
investigate the effect of glucose ﬂuctuations oncoronary plaque properties in patients with CAD
who are under statin administration or other medi-
cal management of dyslipidemia. The main ﬁndings
of this study can be summarized as follows:
1) among patients with CAD referred for PCI under
treatment for dyslipidemia, 86% of the subjects
presented with glucose intolerance, including newly
and formerly diagnosed DM and IGT; 2) in all
patients with CAD who are under treatment for
dyslipidemia, glucose ﬂuctuation is an important
contributing factor to the distribution of plaque
components; and 3) a large glucose ﬂuctuation is the
only independent risk factor for the progression of
necrotic core within the coronary plaque and for-
mation of TCFA.
FIGURE 6 The Correlation Between MAGE and %NC
This ﬁgure shows the correlation between mean amplitude of glycemic excursion (MAGE) and volume percentage of necrotic core within the
plaque (%NC) in (A) DM, (B) IGT, and (C) NGT. Abbreviations as in Figure 1.
TABLE 6 Generalized Linear Mixed Effect Model Adjusted With Confounders for
Determinants of TCFA
Variables
Univariate Multivariate
OR 95% CI p Value OR 95% CI p Value
MAGE 1.029 1.004–1.054 0.021 1.037 1.010–1.065 0.007
DM 5.669 0.852–37.738 0.073
Time in hyperglycemia (h) 1.027 0.998–1.057 0.069
This multivariate model was adjusted by age, sex, DM, and time in hyperglycemia.
CI ¼ conﬁdence interval; OR ¼ odds ratio; other abbreviations as in Tables 1 and 2.
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809GLUCOSE INTOLERANCE AND PROGRESSION OF CAD.
It is well known that DM patients form a high-risk
category among patients with CAD, and the preva-
lence of diabetes has recently been increasing world-
wide. Thus, glucose intolerance has emerged as an
important residual risk for CAD development. Although
a longer DM duration has been associated with the
progression of coronary plaque vulnerability (14), even
in the early stage of IGT, the progression of CAD has
already started and affects the patient outcomes (15).
Recently, it has been reported that glucose ﬂuctuation,
such as hypoglycemia and post-prandial hyperglyce-
mia, arises from an early stage of glucose intolerance
and may be an important contributing factor to the
development of CAD as a residual risk, apart from
dyslipidemia (3,5). In this study, the longer time in
hypoglycemia and higher CRP level was signiﬁcantly
associated with the higher %NC in the non-DM pa-
tients, suggesting that from the early stage of glucose
intolerance, hypoglycemia may cause inﬂammation
and result in the development of plaque vulnerability.
THE RELATIONSHIP BETWEEN GLUCOSE FLUCTUATION
AND CORONARY PLAQUE PROPERTIES. The present
study showed that glucose ﬂuctuation had a stronger
positive correlation with %NC than with the duration of
DM in DM patients. Moreover, multivariate analysis
revealed that glucose ﬂuctuation was independently
associated with the formation of NC in non-DM pa-
tients. Previous investigators have suggested that a
large glucose ﬂuctuation by CGM is associated with
endothelial dysfunction (16,17). Monnier et al. (16) re-
ported that, by evaluating the correlation between
oxidative stress estimated from 24-h urinary excretion
rates of free 8-iso prostaglandin F2 and glucoseﬂuctuation obtained from CGM, glucose ﬂuctuations
exhibited a more speciﬁc triggering effect on oxidative
stress than did chronic sustained hyperglycemia. In
addition, Risso et al. (18) explored the effect of ﬂuctu-
ating glucose on endothelial cells. The investigators
determined that apoptosis was enhanced in human
umbilical vein endothelial cells exposed to intermit-
tent, rather than constant, high glucose concentration.
These investigations suggested that daily glucose ﬂuc-
tuation could have a powerful effect on the promotion
of plaque vulnerability, as observed in this study.
THE RELATIONSHIP BETWEEN GLUCOSE FLUCTUATION
AND TCFA. Previous studies demonstrated that,
compared with non-DM patients, DM patients had a
higher proportion of NC and calcium within the pla-
que and a greater presence of TCFA by VH-IVUS
analysis, which is a surrogate marker of unstable
coronary plaque and future coronary events (14).
A recent report suggests that a large glucose ﬂuctua-
tion is associated with the progression of atheroscle-
rosis, leading to an ACS (19). The present study
demonstrated that a large glucose ﬂuctuation had an
effect on the formation of TCFA in all subjects.
PERSPECTIVES
WHAT IS KNOWN? Beyond dyslipidemia man-
agement, large glucose ﬂuctuation, such as post-
prandial hyperglycemia, may lead to adverse
clinical events in CAD. However, mechanisms for
its deteriorative effects are unknown.
WHAT IS NEW? Mean amplitude of glycemic
excursion, representing daily glucose ﬂuctuation,
was strongly associated with the progression of
vulnerable coronary lesions even under adequate
lipid-lowering therapy.
WHAT IS NEXT? Whether early detection and
management of glucose ﬂuctuation could stabilize
coronary lesions and improve clinical outcome should
be addressed in large-scale clinical trials.
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810A dramatic glucose ﬂuctuation, especially hypogly-
cemia, induced the activation of the sympathetic
nervous system (20), followed by elevated blood
pressure and vasoconstriction. As a result, these
phenomena might cause the progression of vulner-
able plaque, characterized by TCFA (21).
Several observational studies reported that the strict
control of diabetes at an earlier stage helps to prevent
macroangiopathy (22), suggesting a need for the earlier
diagnosis and treatment of diabetes and glucose intol-
erance. The present study demonstrated that the per-
centage of ﬁbrous component had a negative correlation
with MAGE, whereas the percentage of calcium had a
positive correlation. This suggests that the control of
glucose ﬂuctuation may be beneﬁcial to prevent the
formation of TCFA or to stabilize vulnerable plaque. A
large-scale prospective study is warranted to evaluate
whether additional glucose ﬂuctuation control will de-
crease the progression of TCFA and late clinical events.
STUDY LIMITATIONS. First, this was a single-center
study with a relatively small number of patients;
thus, there was a potential risk of patient selection
bias. Second, we only assessed patients with stable
angina pectoris. We excluded ACS patients from this
study because this population was highly heteroge-
neous with multiple confounding factors, such as
uncontrolled dyslipidemia, stress hyperglycemia, and
drastic changes in diet and medications after admis-
sion. Further study is warranted including ACS
patients, because, as vulnerable plaques are more
frequently found, they might be a better target to
address the inﬂuence of MAGE on plaque characteris-
tics. Third, we did not validate the VH-IVUS data with
histological ﬁndings; therefore, the regions identiﬁed
as VH-TCFA were not conﬁrmed to contain a large
necrotic core overlapping with a thin cap. However,
there are no 1-on-1 VH-IVUS criteria that have been
validated with histological ﬁndings for the identiﬁca-
tion of TCFA. Moreover, the ability of VH-IVUS to
identify lipidic components accurately has been vali-
dated previously (23). Therefore, the information
obtained in this study seems to be valid, but a patho-
logical validation of VH-IVUS–based criteria for the
identiﬁcation of TCFA is warranted to further conﬁrm
these results. Fourth, we excluded patients whose LDL
cholesterol level was >120 mg/dl under statin treat-
ment or>100mg/dl without statins, and included only
patients who were thought to be well controlled in the
treatment of dyslipidemia. A previous report sug-
gested %NC was strongly inﬂuenced by the plasma
level of LDL (24). To reduce the inﬂuence of the lipid
proﬁle, we excluded patients with uncontrolled
lipid levels. To explore the direct effect of glucoseﬂuctuation on coronary vulnerability, further study is
warranted to include only patients with more strictly
controlled dyslipidemia; that is, LDL <70 mg/dl.
Finally, there might be a potential interaction among
DM, MAGE, and %NC because HbA1c, a marker of
averaged blood glucose level, MAGE, and %NC were
higher compared with levels in non-DM patients.
However, the correlation coefﬁcient between HbA1c
and MAGE was very poor in DM patients (r ¼ 0.22), and
no correlation was found in non-DM patients. This
suggests that a high level of average blood glucose does
not always indicate high MAGE. The result of multi-
variate analysis that higher MAGE was the indepen-
dent predictor of %NC is of scientiﬁc value.
CONCLUSIONS
Daily glucose ﬂuctuations may have an effect on cor-
onary plaque vulnerability in patients with CAD pre-
treated with lipid-lowering therapy, marking glucose
ﬂuctuation as an important target for management,
apart from the control of dyslipidemia. Further in-
vestigations should address the rationale of early
detection and control of glucose ﬂuctuation in the era
of the universal use of statins for CAD patients.
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